• /search
  • Servizi
  • Crea un podcast
  • Spreaker
  • Piani e prezzi
  • Ascolta
  • Accedi Registrati
  • Distribuzione
  • Monetizzazione podcast
  • Statistiche per i podcast
  • Podcasting per aziende
  • App di registrazione
  • App per l’ascolto
  • Featured This Week
  • Spreaker's Prime Shows
  • Staff Picks
  • Crime
  • This NFL life 🏈
  • Scopri di più
  • Servizi
    • Distribuzione
    • Monetizzazione podcast
    • Statistiche per i podcast
    • Podcasting per aziende
    • App di registrazione
    • App per l’ascolto
  • Crea un podcast
  • Piani e prezzi
  • Ascolta
    • Featured This Week
    • Spreaker's Prime Shows
    • Staff Picks
    • Crime
    • This NFL life 🏈
    • Scopri di più
  • Registrati SIGN IN
← Esplora

#pinder

Tag collegati:

#mary #grace #cancer #swedish #center
  • How should we integrate new immunotherapies into treatment strategies for lung cancer?

    How should we integrate new...

  • Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

    Is there a role for molecul...

  • Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

    Do you need Avastin in firs...

  • Are molecular markers just for NSCLC?

    Are molecular markers just ...

  • Can we predict which patients will benefit from Tarceva based on a blood test?

    Can we predict which patien...

  • What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

    What have we learned from t...

  • Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

    Can we improve on XALKORI? ...

  • Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?

    Is nindetanib a new agent w...

  • Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

    Is there a best Avastin-con...

  • Could BRAF be a new target in NSCLC?

    Could BRAF be a new target ...

  • Is it possible to test for biomarkers in lung cancer on a national scale?

    Is it possible to test for ...

  • How do we approach acquired resistance to targeted therapies in lung cancer?

    How do we approach acquired...

  • Is there a place for maintenance therapy in extensive stage NSCLC?

    Is there a place for mainte...

  • Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?

    Can addition of a "hea...

  • Can we target KRAS effectively in advanced NSCLC?

    Can we target KRAS effectiv...

  • 2 Rent or Not 2 Rent

    2 Rent or Not 2 Rent

  • Ep. 106 Neurodiversity and Special Needs

    Ep. 106 Neurodiversity and ...

Altro Sto caricando
Spreaker logo
  • Piani e prezzi
  • Chi siamo
  • Voxnest
  • Blog
  • Lavora con noi
  • Press
  • Scegli una lingua

Per podcaster ed editori

  • Podcasting per aziende
  • Monetizzazione podcast
  • Statistiche per i podcast
  • Distribuzione

Strumenti per i podcaster

  • Come creare un podcast
  • Store di Spreaker
  • App Studio di Spreaker
  • Centro assistenza

Per gli ascoltatori

  • App Podcast di Spreaker

Other Pages

  • Termini
  • Privacy

Categorie principali

  • Featured This Week
  • Spreaker's Prime Shows
  • Staff Picks
  • Crime
  • This NFL life 🏈
  • Scopri di più

Categorie principali

  • Featured This Week
  • Spreaker's Prime Shows
  • Staff Picks
  • Crime
  • This NFL life 🏈
  • Scopri di più

Seguici su

  • Icona di Facebook Facebook
  • Icona di Twitter Twitter
  • Icona di LinkedIn LinkedIn
  • Icona di Instagram Instagram
Marchio soci IAB

    Other Pages

  • Termini
  • Privacy

Seguici su

Icona di Facebook Facebook
Icona di Twitter Twitter
Icona di LinkedIn LinkedIn
Icona di Instagram Instagram
iAB member
Copyright 2021 - Spreaker Inc. a Voxnest Company - Crea un podcast - New York, NY
Privacy
Termini